Acceleron Pharma and Celgene initiate phase 2 study of ACE-536 Acceleron Pharma announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes, or MDS. MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia. Acceleron is developing ACE-536 in a global collaboration with Celgene. Acceleron earned a $10M milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200M for the ACE-536 program.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.